Repaglinide R-Isomer Ethyl Ester - Names and Identifiers
Repaglinide R-Isomer Ethyl Ester - Physico-chemical Properties
Molecular Formula | C29H40N2O4
|
Molar Mass | 480.64 |
Density | 1.093 |
Melting Point | 122-124℃ |
Boling Point | 664.1±55.0 °C(Predicted) |
pKa | 14.79±0.46(Predicted) |
Storage Condition | Room Temprature |
Repaglinide R-Isomer Ethyl Ester - Introduction
2-Ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(1-piperidinyl)) phenyl]butyl]amino]-2-oxoethyl]benzoic acid ethyl ester is an organic compound commonly abbreviated as OPBAD. Its molecular formula is C31H40N2O5.
Nature:
-Appearance: OPBAD is a colorless liquid.
-Melting point/Boiling Point: The melting point of OPBAD is -5.5 ℃, and the boiling point is 466.6 ℃.
-Solubility: OPBAD has good solubility in common organic solvents, such as ether, dimethylformamide and methanol.
Use:
OPBAD is mainly used as a pharmaceutical intermediate and has certain applications in the field of medicine. It can be used in the synthesis of some anticancer and antiviral drug precursors, such as the anticancer drug Pertuzumab.
Method:
The preparation method of OPBAD is complicated and involves a multi-step reaction. A common synthetic method is to use phenylacetic acid as raw material, through the acylation reaction, bromination reaction, hydrogenation reaction and other steps to synthesize the target product.
Safety Information:
Specific safety information and toxicity data for OPBAD are not currently available for this compound, so it should be used or handled in accordance with relevant safety practices. In any chemical laboratory, appropriate safety measures should be taken, including wearing protective gloves, lab clothes and safety glasses, and operating in a well-ventilated environment. When handling this compound, follow appropriate laboratory procedures and take care to avoid contact with skin and eyes and to avoid inhaling its gases or dust. If you have any problems or unexpected situations, you should immediately seek medical help or consult a professional.
Last Update:2024-04-09 21:54:55